Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | AKT2 | P31751 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.30 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL925570 | 0.77 | — | — | |
| SCHEMBL20578549 | 0.77 | KCNH2 (0.40) | KCNH2LMNAAPEX1PMP22HAO1 | |
| SCHEMBL31504928 | 0.75 | HAO1 (0.49) | KCNH2LMNAAPEX1PMP22HAO1 | |
| SCHEMBL20409158 | 0.73 | — | — | |
| SCHEMBL20437884 | 0.72 | KCNH2 (0.38) | KCNH2LMNAAPEX1PMP22HAO1 | |
| SCHEMBL19303487 | 0.72 | KCNH2 (0.38) | KCNH2LMNAAPEX1PMP22HAO1 | |
| SCHEMBL29312363 | 0.72 | HAO1 (0.34) | KCNH2LMNAAPEX1PMP22HAO1 | |
| SCHEMBL4497205 | 0.72 | — | — | |
| SCHEMBL527210 | 0.70 | APP (0.52) | HAO1AKT1AKT2 | |
| SCHEMBL923185 | 0.69 | NOS2 (0.38) | KCNH2LMNAAPEX1PMP22AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059198-A1 | BRM DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2025-02-20 | — | — | US | disclosed |
| EP-4436966-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118679160-A | BRM targeting compounds and related methods of use | 阿维纳斯运营公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2023097031-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097031-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-3181564-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | HOFFMANN LA ROCHE (CH) | 2019-09-18 | — | — | EP | disclosed |
| US-9890152-B2 | Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890152-B2 | Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890152-B2 | Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2922851-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-2012759-A1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| EP-1841768-B1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| WO-2007121923-A1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| EP-1841768-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006074925-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| EP-0918756-B1 | PARASITICIDAL PYRAZOLES | PFIZER LTD (GB) | 2004-02-25 | — | — | EP | disclosed |
| US-6028096-A | Parasiticidal pyrazoles | PFIZER INC (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0918756-A1 | PARASITICIDAL PYRAZOLES | Pfizer Limited (GB) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998004530-A1 | PARASITICIDAL PYRAZOLES | PFIZER LIMITED (GB) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059198-A1 | BRM DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, RBX1, BRAP | KCNH2 4871/4885LMNA 1460/4885APEX1 1339/4885 |
| US-20080207648-A1 | Organic Compounds | ADORA2A, ADORA1, ADORA3 | KCNH2 1289/4885LMNA 3576/4885APEX1 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.